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ABSTRACT 
The periodic fever syndromes are autoinflammatory diseases. The great majority present in 
infancy or childhood and are characterized by recurrent episodes of fever and systemic 
inflammation that occur in the absence of autoantibody production or identifiable infection.  
The best recognised disorders include CAPS, FMF, TRAPS, and MKD. Understanding of the 
molecular pathogenesis of these disorders provides unique insights into the regulation of 
innate immunity.  
Diagnosis relies on clinical acumen, and is supported by genetic testing. With the exception 
of FMF, which is prevalent in populations originating from the Mediterranean, these 
syndromes are rare and easily overlooked in the investigation of recurrent fevers.  
Disease severity varies from mild to life threatening and one of the most feared complication 
is AA amyloidosis. Effective therapies are available for many of the syndromes including 
colchicine, IL-1 blockade, anti TNF therapies and there is increasing interest in blocking 














Periodic fever syndromes, autoinflammation, cryopyrin associated periodic syndromes 
(CAPS), familial Mediterranean fever (FMF), NLCR4, tumour necrosis factor (TNF) receptor 
associated periodic syndrome (TRAPS), Mevalonate kinase deficiency (MKD), Pyogenic 
arthritis, pyoderma gangrenosum and acne (PAPA), Majeed Syndrome, LPIN-2,  Deficiency 
of IL‐1 receptor antagonist (DIRA), Deficiency of IL‐36 receptor antagonist (DITRA), Blau, 
Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature 
syndrome (CANDLE), STING-associated vasculopathy of infancy (SAVI), Aicardi-
Goutieres Syndrome, Deficiency of adenosine deaminase 2 (DADA2), Periodic fever, 
aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA), 
 
A Introduction 
The periodic fevers syndromes are a group of disorders of innate immunity that can cause 
multisystem inflammation presenting as unexplained fluctuating or recurrent episodes of 
fever usually accompanied by inflammation affecting the joints, eyes, skin or serosal 
surfaces. The term autoinflammatory was coined in 1999 as: “clinical disorders marked by 
abnormally increased inflammation, mediated predominantly by the cells and molecules of 
the innate immune system, with a significant host predisposition”(1).  
 
Over the last 20 years at least 30 separate genes have been implicated in the hereditary 
diseases (infevers, http://fmf.igh.cnrs.fr/ISSAID/infevers) as well an increasing number of 
polygenic and/or acquired syndromes. It is now clear that autoinflammation can result from a  
variety of pathogenic mechanisms including: inflammasomopathies with dysregulated 
production of interleukin 1 as seen in Familial Mediterranean fever (FMF) and the cryopyrin 
associated periodic fever syndrome CAPS ; intracellular stress resulting in production of 













associated periodic syndrome (TRAPS) and mevalonate kinase deficiency (MKD); defective 
regulatory mechanisms affecting cytokine signalling or loss of function of inhibitors as seen 
in deficiency of IL-1 receptor antagonist (DIRA) and deficiency of IL-36 Rn (DITRA); 
enhanced NF kappa B signalling as seen in Blau syndrome; increased interferon signalling in 
SAVI and CANDLE or deficiency of enzymes such as adenosine deaminase 2(2).  In addition 
to inherited forms the most prevalent disease seen in paediatric practice is PFAPA (Periodic 
Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis).  
 
A Recognising Autoinflammatory Diseases 
As with all rare diseases diagnosis relies on a high index of suspicion. As a group, the 
systemic autoinflammatory diseases deserve considerable disease awareness as, almost 
uniquely they combine  severe disease, often with early onset, and a risk of irreversible long 
term complications with, for the most often seen syndromes, excellent responses to highly 
specific and well tolerated, albeit often expensive, treatments. Unfortunately there are still 
considerable diagnostic delays and many patients will have seen five or more hospital 
specialities before a diagnosis is made(3). 
 
Investigation of the patient with a suspected autoinflammatory disease is often challenging as 
the differential diagnosis is wide and somewhat age dependent(4). As in most areas of 
medicine, the mainstay is a good clinical case history and physical examination. Many 
conditions can mimic autoinflammatory diseases. Immunodeficiency including cyclic 
neutropenia, occult or recurrent infections are important differential diagnosis as well as 
malignancy and atypical connective tissue diseases. It is vital to ascertain that symptomatic 
attacks are accompanied by a marked inflammatory response, as this is a hallmark of 













ethnicity in detail. A patient diary is often valuable in assessing the frequency and duration of 
attacks as well as symptoms and any evidence of precipitating factors.  
 
The clinical picture will give a clue as to which hereditary periodic fever syndrome might 
cause the symptoms but in the clinical presentation of the different diseases can overlap 
considerably. Furthermore, at least 40% of patients with a probable autoinflammatory disease 
do not fit with any of the known diseases. The understanding of these “undifferentiated” 
disorders need to be improved.  However, the increasing knowledge of the pathogenesis of 
autoinflammatory diseases in combination with the development of functional assays and the 
potential for therapeutic trials of cytokine inhibitors can permit better treatment. 
 
A Inflammasonopathies 
B Cryopyrin-associated periodic syndromes (CAPS) 
C Pathogenesis 
CAPS is due to gain of function mutations in NLRP3 a key component of the IL-1 
inflammasome. Mutations result in constitutive over-activation of the inflammasome and thus 
caspase 1 mediated cleavage of pro IL-1 to active IL-1 β(5). Although IL-1 production is 
regulated at multiple levels from gene expression onwards, CAPS provides clear evidence 
both that cleavage by caspase 1 is the key step in production of IL-1 β and also that over 
production of IL-1 β itself drives increased gene expression of components of the entire IL-1 
pathway thereby enhancing its own production(6).  The NLRP3 inflammasome can be 
activated by a range of factors, including potassium efflux, mitochondrial reactive oxygen 
species, changes in extracellular calcium levels and lysosomal release of cathepsin B, and 
crystals such as uric acid thus implicating this pathway in a variety of acquired diseases such 














Most of the disease causing mutations are found in NLRP3 exon 3 encoding the NACT 
domain but mutations are also recognised in other exons. In severe disease mutations are 
frequently private whereas in mild spectrum disease more than half of reported patients are 
heterozygous for one of three common mutations: R260W, T348M or A439V(7).  Although 
CAPS is classically inherited in an autosomal dominant pattern, a substantial proportion of 
patients with clinical features of CAPS have somatic rather than germline mutations. Somatic 
mutation has been reported both in up to 50% of cases of severe disease and in 10% of much 
more typical mid-spectrum disease (Rowczenzio D et al Frontiers in Immunology  2015 in 
press). 
 
C Clinical features 
CAPS is a rare disease affecting one to three per million with no gender or ethnic 
predisposition. It was historically considered as three distinct clinical diseases: familial cold 
autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and chronic infantile 
neurological, cutaneous and articular syndrome (CINCA)/neonatal-onset multisystem 
inflammatory disorder (NOMID). These are now recognised as a severity spectrum rather 
than separate entities. Excess IL-1 production produces chronic inflammation which 
manifests from birth as fever, fatigue and characteristic urticarial rash and red eyes. 
Irreversible damage can include sensorineural hearing loss with childhood onset, vision loss 
due to inflammation affecting the eye at any level from the cornea to the optic nerve, skeletal 
deformities, cognitive disability and systemic AA amyloidosis(7). Acute symptoms can occur 
intermittently, often precipitated by cold or damp environments.  Many patients will have 
daily symptoms with a typical diurnal pattern and worsening symptoms as the day progresses 














The symptoms of CAPS are sufficiently characteristic that validated diagnostic criteria have 
been developed. Evidence of raised inflammatory markers (CRP/SAA) plus two or more of 
six CAPS-typical signs/symptoms: urticaria-like rash, cold-triggered episodes, sensorineural 
hearing loss, musculoskeletal symptoms (arthralgia/arthritis/myalgia), chronic aseptic 
meningitis and skeletal abnormalities (epiphyseal overgrowth/frontal bossing) provides a 




Outcomes in CAPS were completely revolutionised by the recognition of the role of IL-1 
blocking agents in the early 2000s (10). Three separate anti IL-1 agents are currently licenced 
for the treatment of CAPS: anakinra (recombinant IL-1 receptor antagonist) from aged eight 
months(11), rilonacept (anti IL-1 TRAP) from aged 2 years(12) and canakinumab (a fully 
human monoclonal antibody with high specificity for IL-1 β) from aged two years(13). All of 
these biologics are given by subcutaneous injection and all have shown remarkable efficacy 
in completely abolishing CAPS associated symptoms and signs with normalisation of the 
acute phase response and dramatic improvements in quality of life. There are a few case 
reports of reversal of deafness in children with treatment and it is hoped that prompt initiation 
of treatment in childhood may prevent disease associated damage in the first place. Long 
term treatment has been used for 15 years with excellent responses in terms of clinical 
disease and quality of life. Safety data to date has been encouraging although treatment is 
undoubtedly associated with an increase in infections and a small risk of modest neutropenia. 
Live vaccinations are contraindicated while on treatment although there is no concrete 













in canakinumab treated individuals(14). Data on pregnancies exposed to anakinra and 
canakinumab are just starting to emerge. There is most experience with anakinra although the 
number of cases remains very limited. There is some concern about the development of the 
renal tract as there have been two cases of renal agenesis in anakinra exposed pregnancies 
(neither mother had CAPS) but no other fetal anomalies have been reported(15). 
 
B Familial Mediterranean Fever (FMF) 
C Pathogenesis 
Mutations in MEFV, a 10 exon gene located on chromosome 16 (16p13.3), were found to be 
associated with FMF in 1997(16, 17). The gene encodes a 781 amino acid protein, pyrin and 
more than 310 MEFV sequence variants have been reported (http://fmf.igh.cnrs.fr/infevers/), 
although by no means all variants are associated with a disease phenotype. The majority of 
patients have two mutations although up to 20% of patients are reported to be heterozygote. 
A few mutations are associated with genuinely dominant inheritance, particularly in atypical 
populations including the British(18). The most frequently seen pathogenic variants are all 
located in exon 10: M694V, M694I, M680I, V726A, R761H, A744S; and of these M694V is 
both the most common and associated with the most severe phenotype.  
Evidence-based recommendations have been developed for the use of genetic testing in the 
diagnosis of FMF by the Single Hub and Access point for Pediatric Rheumatology in Europe 
(SHARE) initiative, highlighting that the diagnosis of FMF is clinical and that disease 
associated with homozygous M694V is often more severe(19). 
Current evidence suggests that, unusually for a recessive disease, mutations are gain of 
function. Pyrin is activated when dephosphorylated at Ser208/Ser242 allowing interactions 
with microtubules which are critical for formation of the pyrin inflammasome and thus 













reduced binding of RhoA effector kinases and thus decreased phosphorylation of pyrin 
facilitating formation of the pyrin inflammasome(20). 
The carrier frequency, of up to one in five in high risk populations, has long fuelled 
speculation that the FMF trait may have conferred a survival benefit. Work published in 2014 
suggesting that pyrin is an indirect sensor of a wide variety of bacterial toxins, including 
diarrhoeal toxins, and potentially also Yersinia Pestis, that perturb actin polymerization 
dynamics by modifying Rho GTPases provides a potential mechanism by which activating 
mutations could augment the innate immune response(21). 
C Clinical features 
Familial Mediterranean fever (FMF) is by far the most common of inherited 
autoinflammatory diseases. It is recognised worldwide but is much more prevalent among 
populations originating from the Eastern Mediterranean.  
The symptoms of FMF are recurring attacks of fever and serositis lasting 12 to 72 hours. 
Peritonitic abdominal pain occurs in 80% of attacks and can resemble appendicitis. Indeed 
40% patients undergo laparoscopy before the diagnosis is made. Pleuritic chest pain is seen in 
15-30% of the patients and is unilateral. Acute non-erosive arthritis, usually affecting one or 
two large joints of the lower limb or the sacroiliac joints is seen rarely. Pericarditis and 
testicular involvement are rare. An erysipelas-like erythema during attacks is seen in about 
25% of pediatric patients. This is usually located between the knee and the dorsum of the foot 
and can be associated with arthritis. There is a brief but marked inflammatory response 
during an attack and subclinical inflammation is common between attacks(22). A variety of 














One of the most remarkable features of FMF is that a disease characterised by recurrent 
severe attacks of multisystem inflammation does not result in serious long term complications 
more often.  
The recurrent inflammatory attacks in FMF cause intense acute symptoms and confer a 
markedly increased relative risk of developing AA amyloidosis and eventually end stage 
renal disease. Prior to the colchicine era this was a major cause of mortality particularly 
around the Mediterranean. Other potential complications of FMF include destructive arthritis, 
adhesions, subfertility and vasculitis. Fortunately these remain very rare and, with long term 
prophylactic treatment, recent studies suggest that both complications and mortality for FMF 
appear very close to age matched healthy controls(24). 
C Treatment     
Recent guidelines have been published on the management of FMF(25). The treatment of 
FMF is lifelong colchicine (26-28). It is important to explain that it is only effective as long-
term prophylaxis and that colchicine provides no useful analgesia in acute attacks(29). On 
appropriate doses most patients will be symptom-free and the risk of amyloidosis almost 
completely disappears. Children usually need a higher dose per kilogram than adults (30). 
Colchicine can sometimes, especially in higher doses, give gastrointestinal side effects. A 
temporary reduction in the colchicine dose and a lactose free diet can relieve the 
gastrointestinal symptoms. Cohort studies suggest that colchicine in pregnancy is safe and 
should not be discontinued. Failure to respond to colchicine should prompt a careful review 
of compliance but IL-1 inhibitors have been demonstrated in trials to be effective therapy in 
resistant cases (31-33) and canakinumab was licenced for this indication in 2017 as a result of 
the CLUSTER study (manuscript in preparation). Acute FMF attacks can be treated with non-













classical manifestations but are effective in protracted myalgia, a rare vasculitic complication 
of FMF(34).  
 
B Pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) 
Pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) is an autosomal dominant 
disease with variable penetrance which has only been reported in a small number of kindreds. 
It is caused by mutations in the PSTPIP1 (proline serine threonine phosphatase interacting 
protein 1) gene on chromosome 15 and 25 diseases associated mutations have been described 
to date. The mechanisms by which these cause inflammation are not clear. However, 
PSTPIP1 directly interacts with pyrin, the mutated protein in FMF. Some PAPA-associated 
mutations have been shown to significantly increase binding of PSTPIP1 to pyrin and may 
activate the pyrin inflammasome via p38 mitogen-activated protein kinases signalling. 
PSTPIP1 appears to play a role in the organization of cytoskeletal structures in white cells 
and thus in cell migration, with pyrin modulating the dynamics of these interactions(35). 
PAPA tends to present between 1 and 16 years of age with an oligoarticular pyogenic 
arthritis, sometimes after a mild trauma. Severe cystic acne often develops at puberty. 
Pyoderma gangranosum-like ulcerative lesions occur in some patients as does suppurativa 
hidradenitis (sometimes described as a separate clinical entity Pyoderma gangrenosum, acne, 
and suppurative hidradenitis (PASH))(36). There is no established treatment for this rare 
disorder. PAPA is only partly responsive to treatment with oral and intraarticular steroids.  
Case series have shown variable results on anti-TNF treatment as perhaps more effectively 
with anti-IL-1 treatment(37). The treatment is usually better against the arthritis than the skin 
manifestations. 













De novo gain-of-function mutations of NLRC4, causing a potential lethal autoinflammatory 
syndrome with a diverse phenotype including fever, severe enterocolitis, urticarial type rash 
and macrophage activation syndrome were first reported in two separate publications in 
2014(38, 39). NLRC4 is an inflammasome component which acts as an intracellular sensor of  
pathogen associated molecular patterns. It is activated by NAIP-mediated recognition of a 
variety of bacterial constituents including flagellin or components of bacterial type 3 
secretion systems. How these dominant mutations result in over activation of the 
inflammasome is not yet entirely clear but the report of a clinical response to anti IL-1 
treatments supports this as the disease mechanism.  
 
A Disorders resulting in intracellular stress responses 
B TNF receptor associated periodic syndrome (TRAPS) 
C Pathogenesis 
The TNF-receptor associated periodic fever syndrome (TRAPS) is an autosomal dominant 
disease. It was initially called familial Hibernian fever and renamed in 1999 after the 
discovery of causative mutations in the gene for the tumor necrosis factor receptor 
superfamily member 1A, TNFRSF1A, on chromosome 12(1). The majority of sequence 
variants underlying TRAPS lie within exons 2 to 4, and there appears to be over 
representation of missense substitutions which disrupt structurally important cysteine-
cysteine disulphide bonds in the extracellular domain (Infevers database: 
http://fmf.igh.cnrs.fr/ISSAID/infevers/).  The mechanism(s) by which heterozygous 
TNFRSF1A mutations cause TRAPS remain unclear and probably differ between 














The two commonest TNFRSF1A variants, P46L and R92Q are present in approximately 10% 
of West Africans and 2% of Caucasians respectively.  The vast majority of carriers of these 
two variants are entirely well, and how they cause inflammatory disease in a minority 
remains obscure(42). 
C Clinical features 
TRAPS has an estimated prevalence of approximately one to two per million. It has been 
more frequently reported in Caucasians but this almost certainly reflects ascertainment bias. 
TRAPS is a far less distinct disease entity than familial Mediterranean fever; attacks can be 
discrete or near continuous and are often prolonged, lasting several weeks and accompanied 
by a variety of features including: fever (88%), non peritonitic abdominal pain (74%), rash 
(63%), eye manifestations (43%), pleuritic pain (32%), headache (28%) and 
lymphadenopathy (14%) (43). Symptoms are almost universally accompanied by a marked 
acute phase response and leucocytosis. The median age at presentation is 7 years and attacks 
characteristically are more discrete in children. Most attacks last from less than a week to 3 
weeks but a minority of patients have continuous diseases with exacerbations. Slightly over a 
quarter of patients are aware that attacks can be precipitated and the best recognised  
precipitants are emotional stress; menstrual cycle; fatigue; infections; exercise and 
vaccinations. Untreated TRAPS carries a risk of AA amyloidosis which in a recent series was 
18% of adult patients(44). 
 
C Treatment 
Descriptions of the treatment of TRAPS are largely based on retrospective cohorts but there 
have been a few placebo controlled studies(45). SHARE has produced recommendations for 













Not all attacks need disease modifying treatments and NSAIDs provided some degree of 
symptom relief in approximately 75% of patients but are rarely effective in terminating 
inflammatory episodes. Corticosteroids are useful in terminating attacks but the effect tends 
to wane over time. Most patients require doses in the order of 0.5 to 1 mg/kg and long term 
use carries a high risk of corticosteroid side effects. 
Etanercept has been used in a prospective study which demonstrated significant improvement 
in symptoms and inflammatory parameters but most patients eventually discontinue the drug 
due to declining effect(47). IL-1 blockade with Anakinra is highly effective (48) and the 
remarkable response of TRAPS to IL-1 therapies has been confirmed by an open labelled 
study with canakinumab(49) and in the placebo controlled CLUSTER study which used 
canakinumab in TRAPS, MKD and colchicine resistant FMF (manuscript in submission). 
This latter study has resulted in the licencing of canakinumab to treat all three by both the 
U.S. Food and Drug Administration and the Europeans Medicine Agency in 2017. 
 
B Mevalonate Kinase Deficiency (MKD) 
C Pathogenesis 
Mevalonate Kinase Deficiency (MKD) is a very rare autosomal recessive disease caused by 
hypomorphic mutations in MKD, the gene for mevalonate kinase. Two clinical phenotypes 
are recognized with severity determined by the activity of their leukocyte intracellular 
enzyme. In the autoinflammatory disease residual enzyme activity is at about 10% whereas in 
the inherited disorder of metabolism, mevalonic aciduria, there is almost no detectable 
enzyme activity. Diagnosis relies on supportive test results: either two MVK mutations or one 
mutation in combination with an abnormal metabolic studies, either increased urinary 
mevalonic acid with attacks or reduced mevalonate kinase enzyme activity in leukocytes or 













longer regarded as a useful diagnostic test(50). More than 170 mutations have been reported 
in association with disease of which two are much the commonest. In the largest series to 
date V377I was reported in 84% of patients and 12% of patients were homozygotes. The 
second most frequent mutation was I268T, occurring in 25% of the patients although none 
were homozygotes(51). 
Mevalonate kinase is involved in the sterol and isoprenoid biosynthetic pathway converting 
mevalonate acid to mevalonate-5-phosphate. The pathologic mechanisms of 
autoinflammation in MKD is poorly understood but reduced synthesis of isoprenoid lipids 
downstream of MVK, in particular geranylgeranyldiphosphate are thought to play a central 
role(52). These are necessary for prenylation (the addition of a hydrophobic compound) of 
small GTPases including RhoA and Rac1. These small GTPases are involved regulation of 
the cytoskeleton and trafficking of vesicles, and the prenylation moiety is involved in their 
localization to membrane. Reduced prenylation of GTPases appear to result in altered 
autophagy, mitochondrial potential, and redox balance with over activation of the pyrin 
inflammasome and consequently dysregulated production of IL-1β(53). 
C Clinical features 
The most common phenotype is a periodic fever syndrome, initially called 
hyperimmunoglobulin D and periodic fever syndrome (HIDS) and now generally referred to 
as  MKD, which is characterized by an onset in the first six months of life of recurrent three 
to seven day episodes of fever(51). Fever episodes are provoked by specific triggers in almost 
50% of cases, mostly by vaccination, stress, or infection. Typical attacks feature GI upset in 
98% (abdominal pain (88%), diarrhoea (84)%, vomiting (69)%), lymphadenopathy (90%), 
arthralgia (71%), oral aphthae (60%), maculopapular rashes (39%), headache 938%) and eye 
inflammation (15%). Rarer features include macrophage activation syndrome, retinitis 













aciduria (MA), usually associated with MVK enzyme activity of less than 0.5%. MA is 
associated with a high rate of stillbirth; survivors present neonatally with severe systemic 
inflammation, dysmorphic facies, severe failure to thrive, developmental delay, seizures, and 
hepatic involvement. Without bone marrow transplantation most affected children do not 
survive. 
C Treatment 
MKD has proved difficult to treat. Corticosteroids and colchicine are generally disappointing 
although a few patients with mild disease find long-term colchicine helpful. HMGCoA 
reductase inhibitors have been tried(54). A formal trial showed no benefit and current 
understanding of the molecular pathogenies of MKD would suggest that statins should be of 
no benefit or positively unhelpful but a small number of patients report benefit(51).   
In severe disease IL-1 blockade appears most promising and is recommended in recent 
international expert consensus guidance(45, 51).   Unfortunately, therapeutic success is often 
modest with only 30% complete remission, and 70% partial remission in patients treated with 
daily anakinra. Canakinumab, a monoclonal antibody against IL-1β, appears to have superior 
efficacy to anakinra with over half of patients achieving complete response (55) and 
canakinumab is now licenced for the treatment of MKD. Blockade of IL-6 receptor with 
tocilizumab has been reported to be highly effective in a very small number of patients who 
have proved refractory to other treatments(56). 
A Defective regulatory mechanisms 
B Deficiency of the interleukin-1 receptor antagonist (DIRA)  
DIRA is an autosomal recessive disease first reported in 2009 caused by mis-sense and non-
sense mutations in IL1RN, the gene encoding the IL-1-receptor antagonist (IL-1Ra) 
protein(57). Founder mutations have been described in Puerto Rico, the Netherlands, 













unopposed IL-1 receptor activation and thus increased responses to IL-1α and IL-1β. Patients 
present neonatally with skin pustulosis, joint swelling, painful osteolytic lesions, periosteitis 
particularly affecting the distal ribs and the long bones and heterotopic bone formation. 
Patients can develop fevers, often low grade with elevation of acute-phase reactants. Pathergy 
characteristically develops after mechanical skin trauma. Patients with DIRA respond 
dramatically treatment with anakinra. 
B Deficiency of interleukin thirty-six–receptor antagonist (DITRA) 
This extremely rare disease is caused by recessively inherited mutations in IL36RN on 
chromosome 2 and was first described in a large kindred from North Africa and unrelated 
European families(58). It is characterized by recurrent episodes of a generalised sterile 
pustular rash accompanied neutophilia, a marked acute phase response and fever. A few 
patients have reported nail dystrophies, glossitis and oligoarthritis Age at onset varies from 
the neonatal period to the sixth decade. Episodes may be precipitated by stress, pregnancy or 
drugs and can be life threatening. Optimal treatment is not yet entirely clear; there are case 
reports of response to IL-1 blockade(59), anti TNF agents(60),  secukinumab(61) and 
ustikinumab(62). 
B Majeed 
This autosomal recessive syndrome characterized by chronic recurrent multifocal 
osteomyelitis (CRMO), congenital dyserythropoietic anemia, and inflammatory dermatosis 
was first described in 1989(63). The disease was found to be due to mutations in LPIN-2 on 
chromosome 18 in 2005(64). Lipin-2 has recently been found to play a role in regulation of 
the IL-1 inflammasone by inhibiting the activation and sensitization of the P2X7 receptor 
thereby reducing the potassium efflux that is required for inflammasome formation. There is 
also evidence Lipin-2 regulates synthesis of pro–IL-1β via effects on pMAPK(65). Disease 













pain, and the appearance of periarticular soft tissue swelling. Long term complications of 
growth retardation and flexion contractures are well recognised. Consistent with current 
understanding of the pathogenesis, good responses to IL-1 blockade have been reported(66).  
A Enhanced NF-kappa B signalling 
B Blau 
Blau syndrome was first described in 1985 as an autosomal dominant syndrome of sarcoid-
like granulomatous infiltration of the joints (causing camptodactyly), eyes (causing sight 
threatening uveitis), skin and sometimes viscera which typically onsets in the two years of 
life. It is caused by missense mutations in in or near the nucleotide oligomerization domain of 
NOD2/CARD15, a member of the death-domain superfamily. NOD2 mutations have also 
been implicated in familial Crohn’s disease. In Blau syndrome these gain of function 
mutations result in increased NF-κβ activation and a pro-inflammatory state. In common with 
the other dominantly inherited autoinflammatory syndromes of CAPS and TRAPS somatic 
mosaicism has been reported(67). Treatment is frequently disappointing and there is little 
consensus on the best choice of agent.  The largest case series of Blau associated uveitis to 
date reports that 68% of patients are treated with a combination of systemic corticosteroids 
and immunosuppressive drugs and/or biologicals. The most commonly used agents were: 
systemic corticosteroids, methotrexate, adalimumab, infliximab, mycophenolate mofetil, and 
in two cases  thalidomide and one in canakinumab(68). Anti TNF agents may be the most 
promising current therapeutic option, with some reports of complete remission(69). 
 
A Interferonopathies 














The acronym CANDLE, Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and 
Elevated temperature was proposed in 2010 for an autosomal recessive disease caused by 
mutations in PSMB8(70, 71). The syndrome was described in 1939 as Nakajo-Nishimura 
syndrome, with  secondary hypertrophic osteoperiostosis, partial lipomuscular atrophy, 
clubbing, a pernio-like, heliotrope-like or nodular erythema-like rash, periodic fever and joint 
contractures.  
PSMB8 encodes the inducible B5 subunit of the immune proteasome. Proteasomes are 
involved in proteolysis, generating antigenic peptides for class I MHC presentation and 
maintenance of cell homeostasis. Failure of proteolysis leads to increased cellular stress. 
Cytokine profiling and transcriptome analysis are consistent with dysregulation of the IFN 
pathway. Skin biopsies demonstrate a characteristic extensive dermal and subcutaneous 
inflammatory infiltrate of mononuclear cells, atypical myeloid cells, neutrophils, eosinophils, 
and some mature lymphocytes(72). Treatment attempts, including anti TNF agents and the 
interleukin-6 (IL-6) receptor blocker tocilizumab, have proved only partially effective. A 
more rational approach is to use Janus Kinase (JAK) inhibitors to reduce IFN gamma-
inducible protein 10 production and there is an ongoing trial in CANDLE (ClinicalTrials.gov 
Identifier: NCT01724580).  
B STING-associated vasculopathy of infancy (SAVI) 
In 2014 there was a report of a novel inherited autoinflammatory syndrome due to de novo 
mutations in TMEM173 gene which encodes the stimulator of interferon genes (STING), an 
endogenous regulator of type I interferon (IFN) signalling. The affected children present in 
early infancy with systemic inflammation and vasculitic lesions on the skin of the fingers, 
toes, nose, cheeks, and ears, interstitial lung disease, and peripheral gangrene,(73).  Mutations 













type I IFN. No therapy has yet been shown to be beneficial but as with CANDLE a trial of 
JAK inhibitors seems the most rational approach. 
B Aicardi-Goutieres Syndrome 
The Aicardi–Goutières syndrome was first described in 1984 as an early onset familial 
encephalopathy(74). Diagnosis is based on: early-onset encephalopathy with extrapyramidal 
signs and acquired microcephaly; cerebral calcification, particularly in the basal ganglia; 
cerebral white matter abnormalities; cerebral atrophy; cerebrospinal fluid findings of chronic 
lymphocytosis and elevated IFN alpha; recurrent fevers; chilblain lesions on the fingers, toes 
and ears; exclusion of pre-/perinatal infections, in particular the TORCH complex 
(toxoplasmosis, rubella, cytomegalovirus, herpes simplex virus).  Some patients display 
symptoms overlapping with systemic lupus erythematosus and there is also evidence of 
genetic concordance. A genetic cause is found in more than 90% of patients usually with an 
autosomal recessive pattern but Aicardi-Goutieres is genetically heterogenous with seven 
genes identified to date. These included the genes encoding the 3-prime to 5-prime 
exonuclease TREX1 (AGS1), three non-allelic components of the RNASEH2 endonuclease 
complex (AGS2, 3 and 4) and the SAMHD1 protein (AGS5)(75). It is postulated that the 
mutations result in inadequate processing nucleic acid debris, with consequent chronic 
stimulation of innate and acquired immunity. Treatment is symptomatic. 
A Deficiency of adenosine deaminase 2 (DADA2) 
This autoinflammatory syndrome resembles polyarteritis nodosa and was first reported in 
2014(76). Features included episodes of fever, rashes (including the characteristic livedo 
racemosa), cutaneous ulcers, hypertension, peripheral neuropathy, and recurrent ischemic 
lacunar strokes, or, less often, intracranial bleeds. The phenotype can also include cytopenia, 
hypoglobulinaemia and infections. DADA2 is caused by recessively inherited mutations in 













regulator of immune development; deficiency is associated with skewed macrophage 
development towards the M1 pro-inflammatory phenotype. M1 macrophages are known to 
produce TNF-α, which may explain the effectiveness of anti TNF agents in DADA2(77). 
Successful allogeneic haematopoietic stem cell transplantation has been reported in a recent 
cohort of 14 cases(78). 
A Periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA) 
C Pathogenesis 
The mechanisms underlying PFAPA are not understood and are assumed to combine 
polygenic and multifactorial acquired factors. There has been interest in the role that the 
tonsils play given the responses to tonsillectomy. Published studies looking at tonsillectomy 
specimens have failed to identify plausible mechanism although one suggested there might be 
a role for their microbiota which differs from that of healthy controls(79). 
C Clinical features 
Worldwide this is the commonest autoinflammatory disease of childhood. It classically 
presents before the age of 5 years and may preferentially affect boys. Diagnostic criteria were 
defined in 1999: regularly recurring fevers with an early age of onset (<5 years of age), and 
symptoms in the absence of upper respiratory tract infection with at least one of the 
following: aphthous stomatitis; cervical lymphadenitis; pharyngitis; exclusion of cyclic 
neutropenia; completely asymptomatic interval between episodes with normal growth and 
development(80). Attacks usually last three to seven days, and recur at intervals of two to 
eight weeks. Characteristically the attacks are so regular as to be predictable ‘sometimes to a 
point that the parents can predict the time’(81). In most children the disease will remit within 
a few years or by adolescence but attacks have a serious impact on the quality of life of the 














Corticosteroids reliably abort a flare to the point that a failure to respond within hours should 
bring the diagnosis into doubt(81). A number of centres use prophylactic colchicine with 
good effect although rarely complete responses(45). Tonsillectomy resulted in disease 
resolution in 80–90% of episodes in a case series(83). The effectiveness of tonsillectomy in 
PFAPA has been examined in a systematic review which concluded that ‘the evidence 
(supporting tonsillectomy) is of moderate quality … due to the relatively small sample sizes 
of the studies and some concerns about the applicability of the results. Therefore, the parents 
and carers of children with PFAPA syndrome must weigh the risks and consequences of 
surgery against the alternative of using medications. It is well established that children with 
PFAPA syndrome recover spontaneously and medication can be administered to try and 




The autoinflammatory diseases are a growing group of diseases characterised by recurrent or 
continuous inflammation. Although they are rare they have proved remarkable exemplars of 
both translational and reverse translational medicine. The best recognised syndromes of FMF, 
CAPS, TRAPS and MKD have seen outcomes transformed by the availability of effective 
treatments. The finding that all four diseases respond so well to IL-1 inhibition has gone hand 
in hand with elucidation of previously unsuspected molecular mechanisms regulating 
cytokine production and activation. With the discovery of more recent extremely rare 
syndromes it is becoming clear that autoinflammatory phenotypes can be accompanied by 
both immunodeficiency and autoimmunity demonstrating that the innate immune system does 
not function independently and that cross talk between the acquired and innate immune 
systems is significant. There is increasing hope that the remarkable advances in this field in 













and, most topically, atherosclerosis as demonstrated in the publication of the CANTOS trial 
which showed that IL-1 inhibition reduced recurrent cardiovascular events post myocardial 
infarction, independent of lipid-level lowering(85). 
 
 
PRACTICE POINTS -  
: 
• Recognition of the autoinflammatory disorders relies on clinical acumen backed up 
by genetic testing. In an attempt to improve this there are a number of current 
initiatives on defining classification criteria for the commoner  syndromes 
• Recent consensus criteria have been published for the management of 
autoinflammatory diseases in general(46) and FMF in particular(25) 
• Not all patients with autoinflammatory disease require long-term treatment. In those 
that do colchicine is the treatment of choice for FMF. Anti IL-1 treatments are almost 
completely effective in TRAPS, CAPS and DRA and have been used with good 
responses in colchicine resistant FMF, MKD and Blau. 
• Stem cell transplantation may be curative in some diseases and should be considered 




• Late diagnosis is a major issue and development of algorithms to facilitate disease 
recognition would be helpful 
• Approximately 40% of patients with presumed autoinflammatory disease do not fit 
into any of the currently known syndromes and his group requires further study.  
• Expansion of next generation genetic testing has demonstrated that many 
uncharacterised patients have sequence variants of unknown or intermediate 
significance in one or more of the genes known to be associated with 
autoinflammatory disorders. Genetic advances need to be combined with functional 
work to explore the significance of novel variants and common sequence variants of 
unknown significance  
• There has been little work yet exploring the role of the microbiome in altering disease 
presentation and complications. 
• In these rare diseases there is a paucity of well controlled trials and this is particularly 
striking in the interferonopathies 
• There is potential for development of small molecule pharmaceuticals which modify 
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